about
GPER Function in Breast Cancer: An OverviewMiRNAs and Other Epigenetic Changes as Biomarkers in Triple Negative Breast CancerRepurposing drugs for the treatment and control of helminth infectionsRisk determination and prevention of breast cancerMain controversies in breast cancerBreastfeeding and breast cancer risk by receptor status--a systematic review and meta-analysisMedical prevention of breast cancerMicroRNA-223 Increases the Sensitivity of Triple-Negative Breast Cancer Stem Cells to TRAIL-Induced Apoptosis by Targeting HAX-1Src Inhibition Blocks c-Myc Translation and Glucose Metabolism to Prevent the Development of Breast Cancer.Challenges in the Treatment of Triple Negative and HER2-Overexpressing Breast CancerTranscription Factor STAT3 as a Novel Molecular Target for Cancer Prevention.Targeting estrogen receptor-β for the prevention of nonmelanoma skin cancer.Adult adipose-derived stem cells and breast cancer: a controversial relationship.Evolution of breast cancer therapeutics: Breast tumour kinase's role in breast cancer and hope for breast tumour kinase targeted therapyGreen tea compounds in breast cancer prevention and treatmentPhytoestrogens and prevention of breast cancer: The contentious debateValidation of six genetic determinants of susceptibility to estrogen-induced mammary cancer in the rat and assessment of their relevance to breast cancer risk in humansDeregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.Selective estrogen receptor modulators: tissue specificity and clinical utility.Curcumin restores sensitivity to retinoic acid in triple negative breast cancer cellsDiurnal suppression of EGFR signalling by glucocorticoids and implications for tumour progression and treatment.Seven In Absentia Homolog 2 (SIAH2) downregulation is associated with tamoxifen resistance in MCF-7 breast cancer cells.Molecular targets of naturopathy in cancer research: bridge to modern medicine.Combined phosphoproteomics and bioinformatics strategy in deciphering drug resistant related pathways in triple negative breast cancer.Preparation of poly(β-L-malic acid)-based charge-conversional nanoconjugates for tumor-specific uptake and cellular deliveryDietary compound isoliquiritigenin prevents mammary carcinogenesis by inhibiting breast cancer stem cells through WIF1 demethylation.Novel polymorphisms in caspase-8 are associated with breast cancer risk in the California Teachers StudyConformationally Defined Rexinoids and Their Efficacy in the Prevention of Mammary CancersMicroRNA-195-5p is a potential diagnostic and therapeutic target for breast cancer.Targeted therapies in breast cancer: New challenges to fight against resistance.Canonical and new generation anticancer drugs also target energy metabolism.Relationship between RUNX1 and AXIN1 in ER-negative versus ER-positive Breast Cancer.Metabolomics Analysis of Hormone-Responsive and Triple-Negative Breast Cancer Cell Responses to Paclitaxel Identify Key Metabolic Differences.Neurocysticercosis: a review on status in India, management, and current therapeutic interventions.In vitro effects of phenytoin and DAPT on MDA-MB-231 breast cancer cells.Knockdown of ANLN by lentivirus inhibits cell growth and migration in human breast cancer.Advances in Preventive Therapy for Estrogen-Receptor-Negative Breast Cancer.PEGylated chitosan nanoparticles potentiate repurposing of ormeloxifene in breast cancer therapy.Multigene clinical mutational profiling of breast carcinoma using next-generation sequencing.Effects of lapatinib and trastuzumab on vascular endothelial growth factor in experimental corneal neovascularization.
P2860
Q21131274-6BB2DCBF-E08F-4D01-8A82-F99C02DE9805Q26775086-5EFB01D5-F47F-485C-BE17-D46F9EB8C1E4Q26823355-031086BD-3056-4A6E-B56A-4D73066833E9Q26991921-86DA0C1E-A1F8-4AE3-91BA-FE040E69BFE0Q27026673-D526F3E2-E16F-48B5-816A-59CE10BEB494Q28085555-1BE250AB-91AB-46B5-874C-91E53E3C58C1Q28086915-4DE25226-3326-4713-AC56-1082423AD05AQ28554012-55985889-DA14-4766-8C7F-5EDC120E6109Q30679405-24ED184F-70C9-4DF5-B642-BE7ECAE3C688Q33576608-3FFDF9B9-4769-4384-B807-995BCB0E5763Q33820278-759B5F75-55D3-436E-8C58-EA81CBEC4E9AQ33966034-B2B071E4-F63D-41B6-AC9C-651C44B9742FQ33984084-74E411DA-99D9-444A-9F0C-0928EF3BD0A8Q34023653-BC3A94FF-0294-4E57-80CF-8592D856C2D8Q34023742-021CB46F-454A-4597-9F03-DFDD338FD46BQ34031258-213663D7-46ED-4BA9-933C-3B64E2F60097Q34042373-09ACE886-962D-4B5D-A67A-38DBC63BFD37Q34103963-D6EA9C75-9D5B-440B-8F32-B7005AB047D8Q34134828-4B5692B3-C1D7-48FB-ABCD-F0416ED761CCQ34317168-C662843F-CB7C-4BA1-B6B3-97450C268934Q34385041-108AEA91-993D-4C24-B998-ACE670D60657Q34431899-291E9BA8-B0AC-41A4-9DAA-3BA7505A1D98Q34457265-D7893614-7634-42B2-9D46-552BEB2484E1Q34588503-31E31CB1-0028-4E95-A902-621C5FADACAAQ35189737-51D42FF2-0B53-4382-AE4C-D298CC82C0BEQ35833171-A2E1DC4E-CD1B-49C7-B7B8-32C20E50275EQ35892049-979BCC97-0FC9-4058-ACFF-E82FAF04BD99Q37056077-91E2C9CB-1348-4ADF-8A08-744AA4AAF27DQ37588827-C479E7AA-E296-4A52-9C5B-7B19C5BFA6E4Q37743048-01043D3B-E900-4E64-9684-55EF6D30C876Q38208982-8244F6DB-5E4D-4F00-9B64-FDA77E3DDE75Q38722836-C3440282-FA76-4728-B130-F44804152BCAQ38756385-BAFF9A66-3C45-4CD3-A93E-C705897BC7D8Q38806842-D87FB312-15B1-44D2-934F-94C137627CEDQ38849790-24AAD483-6FB3-4BB1-AFC9-71D6673E8434Q38956409-EF17841A-D73D-44CB-A252-3D40C6481D6BQ42561379-B1620BEC-2B86-4CBE-9770-7A2535A43418Q48035376-1F521E24-80E1-401C-9BAD-389365C75BB7Q54239061-4D61B753-5870-434C-88A8-824AF774DDF3Q54293320-D233480D-6C2C-4D70-8601-0DEEE8B9B69C
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 September 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Targeted therapy for breast cancer prevention.
@en
Targeted therapy for breast cancer prevention.
@nl
type
label
Targeted therapy for breast cancer prevention.
@en
Targeted therapy for breast cancer prevention.
@nl
prefLabel
Targeted therapy for breast cancer prevention.
@en
Targeted therapy for breast cancer prevention.
@nl
P2093
P2860
P356
P1476
Targeted therapy for breast cancer prevention.
@en
P2093
Michelle I Savage
Petra den Hollander
Powel H Brown
P2860
P356
10.3389/FONC.2013.00250
P577
2013-09-23T00:00:00Z